Buscar
Mostrando ítems 1-10 de 83
Safety and efficacy of a third dose of BNT162b2 Covid-19 vaccine
(Massachusetts Medical Society, 2022)
Neutralizing antibody titers to Omicron six months after vaccination with BNT162b2 in Colombia
(Lausanne : Frontiers Research FoundationInmunovirologíaSuiza, 2023)
SARS-CoV-2 Neutralizing Antibodies in Chile after a Vaccination Campaign with Five Different Schemes
(2022)
Using levels of neutralizing antibodies (nAbs), we evaluate the successful Chilean SARS-CoV-2 vaccine campaign, which combines different vaccine technologies and heterologous boosters.
From a population-based study performed ...
Neutralizing antibody titers elicited by CoronaVac and BNT162b2 vaccines in health care workers with and without prior SARS-CoV-2 infection
(Oxford University Press, 2022)
We report neutralizing antibody titers (NAbTs) elicited by CoronaVac and BNT162b2 vaccines in healthcare workers with and without prior SARS-CoV-2 infection using both a pseudotype-based assay and a commercial kit. NAbTs ...
Editorial: Comparison of antibody and T cell responses elicited by BBIBP-CorV (Sinopharm) and BNT162b2 (Pfizer-BioNTech) vaccines against SARS-CoV-2 in healthy adult humans
(Springer, 2021-12)
Vaccine development has become the main tool for reducing COVID-19 cases and the severity of the disease. Comparative analyses of adaptive immunity generated by different vaccines platforms are urgently needed. Multiple ...
Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study
(Elsevier, 2022)
Background By July 14, 2021, 81.3 % of adults (aged >= 18 years) in Chile had received a first SARS-CoV-2 vaccine and 72.3% had received a second SARS-CoV-2 vaccine, with the majority of people given Sinovac's inactivated ...